Trial Profile
A prospective trial of Natalizumab and Fingolimod assessing changes in the expression levels of cell trafficking adhesion molecules involved in T cell migration after Natalizumab-withdrawal in patients with Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Sep 2016
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary) ; Fingolimod
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 26 Feb 2016 New trial record